Evidence map›Paper›PMID 29955795›Full record

ArticleThe Journal of clinical endocrinology and metabolism2018

Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations.

Janice B Schwartz, J Christopher Gallagher, Rolf Jorde, Vivian Berg, Jennifer Walsh, Richard Eastell, Amy L Evans, Simon Bowles, Kim E Naylor, Kerry S Jones and 10 more

Abstract readMulticenter Study
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Janice B SchwartzDepartment of Medicine, University of California, San Francisco, California.
J Christopher GallagherCreighton University Medical Center, Omaha, Nebraska.
Rolf JordeTromso Endocrine Research Group, UiT the Arctic University of Norway, Tromsø, Norway.
Vivian BergDivision of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
Jennifer WalshMellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
Richard EastellMellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
Amy L EvansMellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
Simon BowlesMellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
Kim E NaylorMellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
Kerry S JonesMRC Elsie Widdowson Laboratory, Cambridge, United Kingdom.
Inez SchoenmakersMRC Elsie Widdowson Laboratory, Cambridge, United Kingdom.
Michael HolickBoston University School of Medicine, Boston, Massachusetts.
Eric OrwollOregon Health and Science University, Portland, Oregon.
Carrie NielsonOregon Health and Science University, Portland, Oregon.
Martin KaufmannQueen's University, Kingston, Ontario, Canada.
Glenville JonesQueen's University, Kingston, Ontario, Canada.
Roger BouillonKuLeuven, Gasthuisbert, Leuven, Belgium.
Jennifer LaiDepartment of Medicine, University of California, San Francisco, California.
Davide VerottaDepartments of Bioengineering and Therapeutic Sciences and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Daniel BikleDepartment of Medicine, University of California, San Francisco, California.

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
Oregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7M
Equipment Supplement Request for a Research Resource for Ultra-sensitive High Throughput ProteomicsP41GM103493 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI SMITH, RICHARD D · 2012 to 2022
$22.6M
Osteoporotic Fractures in Men (MrOS) - San Francisco Coordinating CenterU01AR066160 · NIAMS · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON · 2013 to 2017
$9.3M
Osteoporotic Fractures in Men (MrOS) - MinneapolisU01AG042145 · NIA · UNIVERSITY OF MINNESOTA · PI ENSRUD, KRISTINE · 2013 to 2019
$5.3M
Osteporotic Fractures in Men (MrOS)- Admin CenterU01AG027810 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2017
$5.1M
Vitamin D Receptor Coactivators in KeratinocytesR01AR050023 · NIAMS · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI BIKLE, DANIEL DAVID · 2004 to 2014
$3.4M
TRAINING IN ENDOCRINOLOGY, DIABETES, NUTRITIONT32DK007674 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI KLEIN, ROBERT FREDERICK · 1993 to 2013
$3.1M
Osteoporotic Fractures in Men (MrOS) - PortlandU01AG042124 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2013 to 2019
$3.0M
Osteoporatic Fractures in Men (MrOS)U01AG042168 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KADO, DEBORAH · 2013 to 2017
$3.0M
Osteoporotic Fractures in Men (Mr. Os) Palo AltoU01AG042143 · NIA · STANFORD UNIVERSITY · PI STEFANICK, MARCIA L. · 2013 to 2017
$3.0M
BLRD VA I01 BX001066BLRD VA I01 BX003814Department of Health 024/0052Medical Research Council MC-A760-5QX00Medical Research Council MC_U105960371Medical Research Council MR/P020941/1Medical Research Council U105960371Medical Research Council U123261351NCATS NIH HHS UL1 TR000128NCATS NIH HHS UL1 TR002369NIAMS NIH HHS K01 AR062655NIAMS NIH HHS R01 AR050023NIAMS NIH HHS R01 AR063910NIAMS NIH HHS U01 AR066160NIA NIH HHS R01 AG015982NIA NIH HHS R01 AG028168NIA NIH HHS R21 AG041660NIA NIH HHS R56 AG015982NIA NIH HHS U01 AG027810NIA NIH HHS U01 AG042124NIA NIH HHS U01 AG042139NIA NIH HHS U01 AG042140NIA NIH HHS U01 AG042143NIA NIH HHS U01 AG042145NIA NIH HHS U01 AG042168NIDDK NIH HHS P30 DK026743NIDDK NIH HHS T32 DK007674NIGMS NIH HHS P41 GM103493
6 · The paper itself

Abstract

Context: The optimal measure of vitamin D status is unknown. Objective: To directly measure circulating free 25-hydroxyvitamin D [25(OH)D] concentrations and relationships to total 25(OH)D in a clinically diverse sample of humans. Design: Cross-sectional analysis. Setting: Seven academic sites. Patients: A total of 1661 adults: healthy (n = 279), prediabetic (n = 479), outpatients (n = 714), cirrhotic (n = 90), pregnant (n = 20), nursing home resident (n = 79). Interventions: Merge research data on circulating free 25(OH)D (directly-measured immunoassay), total 25(OH)D (liquid chromatography/tandem mass spectrometry), D-binding protein [DBP; by radial (polyclonal) immunodiffusion assay], albumin, creatinine, intact parathyroid hormone, and DBP haplotype. Main outcome measures: Distribution of free 25(OH)D (ANOVA with Bonferroni correction for post hoc comparisons) and relationships between free and total 25(OH)D (mixed-effects modeling incorporating clinical condition, DBP haplotype with sex, race, estimated glomerular filtration rate (eGFR), body mass index (BMI), and other covariates). Results: Free 25(OH)D was 4.7 ± 1.8 pg/mL (mean ± SD) in healthy persons and 4.3 ± 1.9 pg/mL in outpatients, with levels of 0.5 to 8.1 pg/mL and 0.9 to 8.1 pg/mL encompassing 95% of healthy persons and outpatients, respectively. Free 25(OH)D was higher in patients with cirrhosis (7.1 ± 3.0 pg/mL; P < 0.0033) and nursing home residents (7.9 ± 2.1 pg/mL; P < 0.0033) than in other groups and differed between whites and blacks (P < 0.0033) and between DBP haplotypes (P < 0.0001). Mixed-effects modeling of relationships between free and total 25(OH)D identified clinical conditions (patients with cirrhosis > nursing home residents > patients with prediabetes > outpatients > pregnant women) and BMI (lesser effect) as covariates affecting relationships but not eGFR, sex, race, or DBP haplotype. Conclusions: Total 25(OH)D, health condition, race, and DBP haplotype affected free 25(OH)D, but only health conditions and BMI affected relationships between total and free 25(OH)D. Clinical importance of free 25(OH)D needs to be established in studies assessing outcomes.

Indexed as

AdultAgedBlack PeopleCross-Sectional StudiesFemaleHaplotypesHumansLiver CirrhosisMaleMiddle AgedNursing HomesOutpatientsPrediabetic StatePregnancyReference ValuesVitamin D25-hydroxyvitamin DVitamin DVitamin D-Binding Protein

Identifiers

PMID29955795
PMCPMC6126881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.